These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 8227233)
1. A comparison of the beta 1-selectivity of conventional metoprolol and metoprolol CR during exercise in healthy volunteers. Akhlaghi S; Maxwell SR; Kendall MJ; Hughes B; Greenhaff P J Clin Pharm Ther; 1993 Aug; 18(4):259-66. PubMed ID: 8227233 [TBL] [Abstract][Full Text] [Related]
2. Exercise metabolism in healthy volunteers taking atenolol, high and low doses of metoprolol CR/Z0K, and placebo. Head A; Maxwell S; Kendall MJ; Eagles C Br J Clin Pharmacol; 1994 Dec; 38(6):499-504. PubMed ID: 7888287 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK once daily with conventional tablets once daily and in divided doses. Lücker P; Moore G; Wieselgren I; Olofsson B; Bergstrand R J Clin Pharmacol; 1990 Feb; 30(S2):S17-27. PubMed ID: 2312775 [TBL] [Abstract][Full Text] [Related]
4. A pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK with a conventional slow release preparation. Oosterhuis B; Jonkman J; Zuiderwijk P; Sollie F J Clin Pharmacol; 1990 Feb; 30(S2):S33-8. PubMed ID: 2312777 [TBL] [Abstract][Full Text] [Related]
5. Effect of controlled-release metoprolol on blood pressure and exercise heart rate in hypertension: a comparison with conventional tablets. Rydén L; Kristensson BE; Westergren G Eur J Clin Pharmacol; 1988; 33 Suppl():S33-7. PubMed ID: 3371392 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic comparison of conventional and controlled release formulations of metoprolol [correction of motoprolol] in healthy Chinese subjects. Lee YT; Liau CS; Wong EC; Chen WJ; Chen MF; Chen CC Cardiovasc Drugs Ther; 1989 Aug; 3(4):529-33. PubMed ID: 2488104 [TBL] [Abstract][Full Text] [Related]
7. Is metoprolol CR/ZOK more selective than conventional metoprolol and atenolol? Kendall M; Akhlaghi S; Hughes B; Lewis H J Clin Pharmacol; 1990 Feb; 30(S2):S98-102. PubMed ID: 2155948 [TBL] [Abstract][Full Text] [Related]
8. Maximal exercise power after a single dose of metoprolol and of slow-release metoprolol. Folgering H; van Bussel M Eur J Clin Pharmacol; 1980 Oct; 18(3):225-9. PubMed ID: 7439241 [TBL] [Abstract][Full Text] [Related]
9. Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease. Plosker GL; Clissold SP Drugs; 1992 Mar; 43(3):382-414. PubMed ID: 1374320 [TBL] [Abstract][Full Text] [Related]
10. CNS-related performance and haemodynamics of metoprolol-Oros and propranolol after single and 3 days dosing in healthy volunteers. van Steveninck AL; Pieters MS; Schoemaker HC; Breimer DD; Cohen AF Br J Clin Pharmacol; 1993 Feb; 35(2):114-20. PubMed ID: 8443028 [TBL] [Abstract][Full Text] [Related]
11. The effects of combined treatment with beta 1-selective receptor antagonists and lipid-lowering drugs on fat metabolism and measures of fatigue during moderate intensity exercise: a placebo-controlled study in healthy subjects. Eagles CJ; Kendall MJ Br J Clin Pharmacol; 1997 Mar; 43(3):291-300. PubMed ID: 9088584 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic comparison of a new controlled-release formulation of metoprolol with a traditional slow-release formulation. Oosterhuis B; Jonkman JH; Kerkhof FA Eur J Clin Pharmacol; 1988; 33 Suppl():S15-8. PubMed ID: 3371389 [TBL] [Abstract][Full Text] [Related]
13. Effects of a week's beta-adrenoceptor blockade with atenolol and metoprolol CR/ZOK on the response to exercise in healthy women aged 50 to 70 years. Patrick J; Bassey J; Morrant J; Macdonald I J Clin Pharmacol; 1990 Feb; 30(S2):S108-16. PubMed ID: 2312773 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of controlled-release metoprolol: a comparison with atenolol. Blomqvist I; Westergren G; Sandberg A; Jonsson UE; Lundborg P Eur J Clin Pharmacol; 1988; 33 Suppl():S19-24. PubMed ID: 3371390 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic properties of controlled release (CR/ZOK) metoprolol in healthy Oriental subjects: a comparison with conventional formulations of metoprolol and atenolol. Darmansjah I; Wong E; Setiawati A; Moeloek D; Irawati D; Siagian M; Muchtar A J Clin Pharmacol; 1990 Feb; 30(S2):S39-45. PubMed ID: 2312778 [TBL] [Abstract][Full Text] [Related]
16. Metabolic aspects of maximal exercise performance after slow release metoprolol and after atenolol. Folgering HT; Borm JF; van Haaren RH Eur J Clin Pharmacol; 1982 Oct; 23(4):283-8. PubMed ID: 7173299 [TBL] [Abstract][Full Text] [Related]
17. Subjective symptoms and pharmacokinetics/dynamics of metoprolol CR in elderly subjects--a comparison with atenolol. Dimenäs ES; Dahlöf CG; Heibel B; Moore RG; Olofsson BK; Westergren GE; Lücker PW Eur J Clin Pharmacol; 1990; 38(6):571-8. PubMed ID: 2373131 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic properties of a new controlled-release formulation of metoprolol: a comparison with conventional tablets. Sandberg A; Blomqvist I; Jonsson UE; Lundborg P Eur J Clin Pharmacol; 1988; 33 Suppl():S9-14. PubMed ID: 3371395 [TBL] [Abstract][Full Text] [Related]
19. The relationship between metoprolol plasma concentration and beta 1-blockade in healthy subjects: a study on conventional metoprolol and metoprolol CR/ZOK formulations. Abrahamsson B; Lücker P; Olofsson B; Regårdh CG; Sandberg A; Wieselgren I; Bergstrand R J Clin Pharmacol; 1990 Feb; 30(S2):S46-54. PubMed ID: 1968913 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and pharmacodynamic evaluation of metoprolol controlled release (CR/ZOK) 50 mg in young subjects. Wieselgren I; Lundborg P; Sandberg A; Olofsson B; Bergstrand R J Clin Pharmacol; 1990 Feb; 30(S2):S28-32. PubMed ID: 2312776 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]